1.00
전일 마감가:
$0.97
열려 있는:
$0.978
하루 거래량:
4.98M
Relative Volume:
17.55
시가총액:
$19.25M
수익:
-
순이익/손실:
$-24.05M
주가수익비율:
-0.4651
EPS:
-2.15
순현금흐름:
$-17.78M
1주 성능:
-79.63%
1개월 성능:
-79.34%
6개월 성능:
-73.47%
1년 성능:
-81.45%
Envveno Medical Corporation Stock (NVNO) Company Profile
명칭
Envveno Medical Corporation
전화
949-261-2900
주소
70 DOPPLER, IRVINE
NVNO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NVNO
Envveno Medical Corporation
|
1.00 | 96.14M | 0 | -24.05M | -17.78M | -2.15 |
![]()
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
![]()
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
![]()
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Envveno Medical Corporation 주식(NVNO)의 최신 뉴스
Midday Stock Roundup: enVVeno Medical plunges 71% - Orange County Business Journal
This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It? - Stocktwits
EnVVeno Medical shares fall 71.12% intraday after FDA issues not-approvable letter for VenoValve. - AInvest
EnVVeno Medical Receives Not-Approvable Letter from FDA for VenoValve, Shares Plummet 70% - AInvest
NVNO Plummets 71% After FDA Rejects VenoValve PMA—What’s Next for enVVeno? - AInvest
enVVeno tanks after FDA rejects VenoValve approval (NVNO:NASDAQ) - Seeking Alpha
Why Is EnVVeno Medical Stock (NVNO) Down 70% Today? - TipRanks
enVVeno Medical Plunges 71.6% After FDA Rejection - AInvest
enVVeno Medical receives not-approvable letter from the FDA for VenoValve - TipRanks
enVVeno Medical Plunges 76.63% After FDA Rejection - AInvest
enVVeno Medical Plunges 77.78% After FDA Rejection - AInvest
enVVeno Medical stock plummets after FDA rejects VenoValve approval - Investing.com
enVVeno Medical Receives FDA Setback for VenoValve - TipRanks
FDA rejects enVVeno Medical’s VenoValve for chronic venous insufficiency - Investing.com
enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R) - ACCESS Newswire
FDA Rejects First-Ever Surgical Venous Valve Treatment: enVVeno's VenoValve Hits Regulatory Roadblock - Stock Titan
Trend analysis for enVVeno Medical Corporation this week2025 Trading Recap & Technical Entry and Exit Alerts - Newser
Signal strength of enVVeno Medical Corporation stock in tech scanners2025 Major Catalysts & Real-Time Sentiment Analysis - Newser
Quant Strategy Flags enVVeno Medical Corporation for EntryJuly 2025 Volume & Risk Managed Investment Signals - Newser
Published on: 2025-08-19 23:43:17 - Newser
Heavy Losses Hit James Hardie, EnVVeno And Calidi Shares - Finimize
Is now a turning point for enVVeno Medical Corporation2025 Breakouts & Breakdowns & Advanced Technical Signal Analysis - Newser
Understanding enVVeno Medical Corporation’s price movementMarket Sentiment Review & Real-Time Volume Trigger Notifications - Newser
enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - The Florida Times-Union
enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Newport Daily News
Is enVVeno Medical Corporation trending in predictive chart modelsJuly 2025 EndofMonth & Daily Profit Focused Screening - Newser
enVVeno Medical to Present at Webull Financial Corporate Connect Webinar on Deep Venous Disease Treatment - AInvest
Key metrics from enVVeno Medical Corporation’s quarterly dataTrade Analysis Summary & Safe Capital Growth Tips - Newser
How high can enVVeno Medical Corporation stock goJuly 2025 Drop Watch & Fast Moving Trade Plans - Newser
Tick level data insight on enVVeno Medical Corporation volatility2025 Support & Resistance & Fast Entry Momentum Alerts - Newser
Can volume confirm reversal in enVVeno Medical CorporationPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - Newser
What makes enVVeno Medical Corporation stock price move sharplyTrade Risk Assessment & Advanced Swing Trade Entry Plans - Newser
How to forecast enVVeno Medical Corporation trends using time seriesProfit Target & Low Risk High Win Rate Stock Picks - Newser
Published on: 2025-08-16 15:22:13 - beatles.ru
XTX Topco Ltd Invests $80,000 in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
Using flow based indicators on enVVeno Medical CorporationJuly 2025 Fed Impact & Stepwise Trade Signal Guides - Newser
enVVeno Medical's Dual-Platform Gambit: A High-Stakes Play in Venous Disease Innovation - AInvest
Deep Venous Disease Treatment Pioneer enVVeno Medical to Showcase at Webull Biotech Conference - Stock Titan
Is it too late to sell enVVeno Medical CorporationWeekly Trend Summary & Weekly High Return Stock Opportunities - Newser
Published on: 2025-08-14 14:16:22 - beatles.ru
Why enVVeno Medical Corporation stock attracts strong analyst attention2025 Investor Takeaways & Weekly Momentum Picks - Newser
Published on: 2025-08-13 13:11:19 - 선데이타임즈
Can enVVeno Medical Corporation be the next market leaderLow Float Big Mover Alerts - sisain.net
Is Now a Good Time to Reenter enVVeno Medical CorporationStock Selection With High Accuracy Based on Models - beatles.ru
How enVVeno Medical Corporation stock performs during market volatilityFree Trend Continuation Signals - newsyoung.net
Envveno Medical Corporation (NVNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Envveno Medical Corporation 주식 (NVNO) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Gray Robert | Director |
Dec 31 '24 |
Buy |
2.94 |
3,500 |
10,290 |
11,155 |
Shrivastava Sanjay | Director |
Dec 24 '24 |
Buy |
2.90 |
5,400 |
15,660 |
9,288 |
Jenusaitis Matthew | Director |
Dec 19 '24 |
Buy |
2.53 |
9,620 |
24,339 |
16,545 |
BERMAN ROBERT ANDREW | Chief Executive Officer |
Dec 19 '24 |
Buy |
2.55 |
12,000 |
30,600 |
222,236 |
자본화:
|
볼륨(24시간):